N/A
FDA Accepts NDA for Menopause Drug, Elinzanetant
If approved, elinzanetant would be another non-hormonal option for menopausal women seeking hot flash relief.
Read More
Report Finds the Money Spent on Healthcare Doesn’t Provide Value
Sanjula Jain of Trilliant Health talks about how employers are best positioned to demand value for money from the U.S. healthcare system.
UnitedHealthcare Adds Deductibles to Medicare Part D for 2025
UnitedHealthcare is adding deductibles to Part D prescriptions on certain formulary tiers as a result of plan design changes from the Inflation Reduction Act.
NDA Resubmitted for Dry Eye Treatment Reproxalap
Dry eye disease affects up to 15% of the U.S. population and is one of the largest markets in the ophthalmology field.
Stelara Biosimilar Otulfi Approved by FDA to Treat Multiple Autoimmune Disorders
Otulfi is the fourth Stelara biosimilar to be approved by the FDA.
Blue Shield of California to Offer Humira Biosimilar Idacio
Blue Shield of California is purchasing Idacio for a net price of $525 per monthly dose, and most plan members will pay $0 out of pocket.
